Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6853743rdf:typepubmed:Citationlld:pubmed
pubmed-article:6853743lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:6853743lifeskim:mentionsumls-concept:C0071144lld:lifeskim
pubmed-article:6853743lifeskim:mentionsumls-concept:C0743223lld:lifeskim
pubmed-article:6853743pubmed:issue2-3lld:pubmed
pubmed-article:6853743pubmed:dateCreated1983-7-29lld:pubmed
pubmed-article:6853743pubmed:abstractTextTwelve patients having frequent premature ventricular complexes (PVCs) averaging more than 60 per hour received a single 150-mg intravenous dose of pirmenol. Plasma pirmenol concentration declined biexponentially following the infusion and was analyzed according to a two-compartment open model. Following an erratic distribution phase, the terminal elimination half-life ranged from 4.2 to 16.9 hours, with a geometric mean of 7.6 hours. Total body clearance averaged 164 +/- 58 ml/min, and the mean volume of distribution was 1.45 +/- 0.38 liter/kg. Renal clearance averaged 46.6 +/- 21.2 ml/min, representing 30 +/- 10 per cent of total body clearance. Excretion of unchanged drug in the urine averaged 31.8 +/- 8 per cent of the dose. Renal clearance and elimination half-life were correlated (r = -0.61, P less than 0.05). Eight of the 12 patients achieved greater than 95 per cent suppression of PVCs with a duration between 20 minutes and 23 hours. These favorable pharmacokinetics indicate that pirmenol may be a useful addition to the therapy of ventricular arrhythmias.lld:pubmed
pubmed-article:6853743pubmed:languageenglld:pubmed
pubmed-article:6853743pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6853743pubmed:citationSubsetIMlld:pubmed
pubmed-article:6853743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6853743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6853743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6853743pubmed:statusMEDLINElld:pubmed
pubmed-article:6853743pubmed:issn0091-2700lld:pubmed
pubmed-article:6853743pubmed:authorpubmed-author:AndersonJ LJLlld:pubmed
pubmed-article:6853743pubmed:authorpubmed-author:SandersS WSWlld:pubmed
pubmed-article:6853743pubmed:authorpubmed-author:FoltzR LRLlld:pubmed
pubmed-article:6853743pubmed:authorpubmed-author:NappiJ MJMlld:pubmed
pubmed-article:6853743pubmed:authorpubmed-author:LutzJ RJRlld:pubmed
pubmed-article:6853743pubmed:issnTypePrintlld:pubmed
pubmed-article:6853743pubmed:volume23lld:pubmed
pubmed-article:6853743pubmed:ownerNLMlld:pubmed
pubmed-article:6853743pubmed:authorsCompleteYlld:pubmed
pubmed-article:6853743pubmed:pagination113-22lld:pubmed
pubmed-article:6853743pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:meshHeadingpubmed-meshheading:6853743-...lld:pubmed
pubmed-article:6853743pubmed:articleTitleDisposition of intravenous pirmenol.lld:pubmed
pubmed-article:6853743pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6853743pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6853743lld:pubmed